YOLFTbeta
Calidi Biotherapeutics Inc.

Calidi Biotherapeutics Inc.

CLDI · AMEX · Healthcare / Biotechnology

0.622USD-0.03 (-5.04%)

Price History

Full chart

Market Stats

Previous Close0.655
Open0.676
Day Range0.621 – 0.676
52-Week Range1.05 – 27.84
Volume27.60K
Market Cap2.92M
P/E (TTM)0.00
Forward P/E0.00
EPS-37.04
Dividend Yield0.00%
Beta1.32
50-Day Avg1.46
200-Day Avg6.96

About

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Eric E. Poma Ph.D.
  • Employees29
  • Headquarters4475 Executive Drive, San Diego, CA, United States, 92121, USA
  • Websitehttps://www.calidibio.com

Leadership

  • Dr. Eric E. Poma Ph.D.CEO & Director · b. 1972
  • Mr. Andrew C. JacksonCFO & Corporate Secretary · b. 1969
  • Dr. Antonio Fernandez Santidrian Ph.D., Pharm.D.Head of Technical Operations & Chief Scientific Officer · b. 1980
  • Dr. Guy Travis Clifton M.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0449.00K45.00K000
Growth (%)---89.98%-100.00%--
Cost of Revenue094.00K274.00K1.26M1.53M1.65M
Gross Profit0355.00K-229.00K-1.26M-1.53M-1.65M
Gross Margin-79.06%-508.89%---
Operating Expense6.77M10.84M22.90M27.74M20.24M18.59M
Operating Income-6.77M-10.48M-23.13M-28.99M-21.78M-20.24M
Operating Margin--2334.52%-51395.56%---
EBITDA-6.67M-9.45M-25.00M-24.20M-19.73M-18.19M
EBITDA Margin--2104.68%-55551.11%---
Net Income-7.94M-10.93M-25.43M-29.22M-22.14M-19.91M
Net Income Margin--2434.97%-56504.44%---
R&D3.18M4.67M7.26M13.01M8.88M9.74M
R&D as % of Total Revenue-1040.98%16126.67%---
Interest Expense163.00K614.00K158.00K3.75M933.00K207.00K
Interest Expense % of Total Revenue-136.75%351.11%---

Balance Sheet

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.85M3.39M2.60M10.02M14.18M8.86M
Total Liabilities24.33M26.00M53.04M18.25M12.21M5.10M
Total Equity-22.48M-22.61M-50.44M-8.23M1.53M3.76M
Cash420.00K2.14M372.00K2.05M9.59M5.60M
Total Debt11.72M5.18M5.99M7.24M7.04M2.56M
Net Debt11.30M3.04M5.62M5.19M-2.56M-3.04M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.83M-7.77M-13.21M-26.98M-19.69M-21.29M
Investing Cash Flow-388.00K-215.00K-494.00K-478.00K-16.00K-170.00K
Financing Cash Flow4.70M9.81M12.09M29.04M27.36M17.46M
Capital Expenditure351.00K206.00K428.00K585.00K16.00K120.00K
Free Cash Flow-5.18M-7.98M-13.64M-27.57M-19.71M-21.41M
Dividends Paid----1.67M5.67M
FCF to OCF107.27%102.65%103.24%102.17%100.08%100.56%
Dividend Paid to FCF-----8.48%-26.49%

Earnings

Report DateSep 13, 2021Nov 12, 2021Mar 31, 2022May 11, 2022Aug 10, 2022Nov 14, 2022Mar 31, 2023Aug 30, 2023Nov 14, 2023Mar 15, 2024May 14, 2024Aug 13, 2024Nov 12, 2024Mar 31, 2025May 14, 2025Aug 8, 2025Nov 13, 2025Aug 13, 2026Nov 12, 2026
EPS Estimate0.000.000.000.000.000.000.00--20.40-0.20-32.40-17.40-10.26-0.09-1.80-1.32-1.68--
EPS Actual0.00-0.030.150.050.140.02-0.26-0.43-63.43-0.48-23.71-16.80-7.80-0.27-2.25-1.99-2.21-2.94-
Surprise---------210.93%-140.00%26.82%3.45%23.98%-200.00%-25.00%-50.76%-31.55%--
Timing--------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours--

Key Statistics & Ratios

Market Cap2.92M
Enterprise Value687.76K
Trailing P/E0.00
Forward P/E0.00
Price / Sales50.83
Price / Book0.90
EPS-37.04
Book Value1.50
Revenue (TTM)0
Gross Profit (TTM)31.00K
EBITDA-16.14M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-672.22%
Return on Assets-134.79%
Shares Outstanding2.58M
Shares Float2.57M
Beta1.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 120.00
  • Strong Buy
    1

Stock Splits

  • Jul 31, 20261:16
  • Aug 5, 20251:12
  • Jul 15, 20241:10